Please login to the form below

Not currently logged in
Email:
Password:

paclitaxel

This page shows the latest paclitaxel news and features for those working in and with pharma, biotech and healthcare.

BMS’ Opdivo wins EU approval for second-line oesophageal cancer

BMS’ Opdivo wins EU approval for second-line oesophageal cancer

The EC approved Opdivo following positive results from the phase 3 ATTRACTION-3 trial, which investigated the PD-1 inhibitor versus chemotherapy docetaxel or paclitaxel – as a treatment for patients with

Latest news

More from news
Approximately 9 fully matching, plus 119 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • BMS appoints oncology development head BMS appoints oncology development head

    Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics